Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Virtual Reality-Based Cognitive-Motor Rehabilitation in Traumatic Brain Injury

10 novembre 2026 aggiornato da: Dr. Gabriel Zeilig

Novel Virtual Reality-Based Cognitive-Motor Rehabilitation for Individuals With Traumatic Brain Injury

This study aims to evaluate the feasibility, safety, and efficacy of a novel virtual reality (VR)-based cognitive-motor rehabilitation program for individuals with traumatic brain injury (TBI). The intervention uses the Virtual Reality Color Trails Test (VR-CTT), which combines cognitive tasks with upper-limb movements in an immersive virtual environment.

The study consists of two stages. The first stage is a feasibility pilot involving 15 participants who will complete three VR training sessions over one week. The second stage is a randomized controlled trial involving 80 participants allocated to either VR-CTT training combined with standard rehabilitation or a control group receiving standard rehabilitation with additional therapy time. The intervention will consist of nine sessions over three weeks.

The study will assess feasibility, safety, executive functions, upper-limb motor performance, balance, and functional outcomes.

Panoramica dello studio

Descrizione dettagliata

Traumatic brain injury (TBI) frequently results in cognitive and motor impairments that affect everyday functioning. Conventional rehabilitation often addresses these domains separately, although many daily activities require their simultaneous integration. This study evaluates a rehabilitation approach based on the Virtual Reality Color Trails Test (VR-CTT), an immersive system developed at Sheba Medical Center that combines cognitive challenges with coordinated head and upper-limb movements.

The study consists of two sequential stages.

**Stage 1: Feasibility Pilot**

Fifteen participants with TBI will receive three VR-CTT training sessions over one week in addition to standard rehabilitation. Training will progress from seated tasks to more challenging standing activities according to individual abilities. This stage will assess feasibility, safety, usability, and participant satisfaction to inform implementation of the subsequent trial.

**Stage 2: Randomized Controlled Trial**

Eighty participants with TBI will be randomly assigned in a 1:1 ratio to two parallel groups. The intervention group will receive standard rehabilitation supplemented by nine VR-CTT training sessions over three weeks. Training difficulty will increase progressively through changes in cognitive demands, the number of targets, body position, and unilateral or bilateral hand use.

The control group will receive standard rehabilitation supplemented by additional cognitive or motor therapy to match the total treatment time of the intervention group.

Outcome assessments will be conducted before and after the intervention period and will include measures of executive functioning, upper-limb motor performance, balance, everyday functioning, and cognitive-motor interaction. Outcome assessors will remain blinded to group allocation during the randomized stage.

The study aims to determine whether integrated VR-based cognitive-motor training is feasible and safe and whether it improves cognitive and motor outcomes compared with conventional rehabilitation.

Tipo di studio

Interventistico

Iscrizione (Stimato)

95

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Ramat Gan, Israele
        • Sheba Medical Center
        • Contatto:
        • Sub-investigatore:
          • Meir Plotnik, Prof.

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 50 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

**Inclusion Criteria:**

  1. Men and women aged 18-50 years.
  2. Admitted for inpatient rehabilitation following traumatic brain injury (TBI).
  3. Glasgow Coma Scale (GCS) score of 9-15 at admission.
  4. Brain CT positive for acute intracranial trauma (including complicated mild or moderate TBI).
  5. Presence of cognitive and motor symptoms as determined by clinical evaluation.
  6. Sufficient decision-making capacity to provide informed consent.

**Exclusion Criteria:**

  1. Inability to meaningfully comprehend the study procedures (e.g., severe aphasia or cognitive impairment), as determined through a structured capacity assessment.
  2. Severe physical limitations that prevent the use of VR equipment (e.g., severe upper-limb fractures preventing controller use).
  3. History of epilepsy or seizures triggered by flashing lights.
  4. Severe visual or vestibular impairments that would make VR exposure unsafe (e.g., severe vertigo).
  5. Active psychiatric conditions (e.g., acute psychosis) likely to interfere with adherence to study procedures.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Stage 1: VR-CTT Feasibility Pilot

Fifteen participants with traumatic brain injury will receive standard rehabilitation supplemented by three VR-CTT training sessions over one week. Sessions will last approximately 45 minutes and progress from seated activities to standing activities according to participants' abilities. This stage will evaluate feasibility, safety, and usability.

An immersive virtual reality-based cognitive-motor rehabilitation program using the HTC VIVE system and custom-developed VR-CTT software. Participants perform cognitive tasks involving visual search, attention, and cognitive flexibility while reaching toward virtual targets using coordinated upper-limb and head movements. Training difficulty is progressively adjusted by modifying the number of targets, cognitive demands, posture, and hand use. The intervention consists of three sessions over one week in Stage 1 and nine sessions over three weeks in Stage 2.

Sperimentale: Stage 2: VR-CTT Training

Forty participants will receive standard inpatient rehabilitation supplemented by nine VR-CTT training sessions over three weeks (three sessions per week, approximately 45 minutes each). Training will progressively increase cognitive and motor demands through changes in target number, task complexity, posture, and hand use.

An immersive virtual reality-based cognitive-motor rehabilitation program using the HTC VIVE system and custom-developed VR-CTT software. Participants perform cognitive tasks involving visual search, attention, and cognitive flexibility while reaching toward virtual targets using coordinated upper-limb and head movements. Training difficulty is progressively adjusted by modifying the number of targets, cognitive demands, posture, and hand use. The intervention consists of three sessions over one week in Stage 1 and nine sessions over three weeks in Stage 2.

Comparatore attivo: Stage 2: Active Control

Forty participants will receive standard inpatient rehabilitation supplemented by approximately three hours per week of additional cognitive or motor therapy with a therapist or volunteer, without VR-CTT training. The additional therapy is intended to match the total treatment time of the intervention group.

Additional cognitive or motor rehabilitation exercises administered by a therapist or volunteer, supplementing standard inpatient rehabilitation. Participants receive approximately three hours of additional therapy per week over three weeks to match the total treatment time provided to the VR-CTT intervention group.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Executive Function Composite Score
Lasso di tempo: Baseline (Week 0) and post-intervention (Week 4).

Change in executive functioning assessed using a composite score derived from the Stroop Test, Rule Shift Cards Test (BADS), and Montreal Cognitive Assessment (MoCA). Standardized scores will be used to evaluate changes in executive control, including inhibition, cognitive shifting, and mental flexibility.

Baseline (Week 0) and post-intervention (Week 4).
Change in Upper Limb Motor Function (ARAT)
Lasso di tempo: Baseline (Week 0) and post-intervention (Week 4).

Change in upper limb motor function assessed using the Action Research Arm Test (ARAT), which evaluates upper extremity motor performance and coordination. Higher scores indicate better motor function.

Baseline (Week 0) and post-intervention (Week 4).

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Functional Status (FSE)
Lasso di tempo: Baseline (Week 0) and post-intervention (Week 4).

Change in everyday functional outcomes assessed using the Functional Status Examination (FSE), which evaluates functional limitations following traumatic brain injury.

Baseline (Week 0) and post-intervention (Week 4).
Change in Balance (Berg Balance Scale)
Lasso di tempo: Baseline (Week 0) and post-intervention (Week 4).

Change in static and dynamic balance assessed using the Berg Balance Scale (BBS). Higher scores indicate better balance performance.

Baseline (Week 0) and post-intervention (Week 4).
Change in Cognitive-Motor Performance (VR Supermarket Task)
Lasso di tempo: Baseline (Week 0) and post-intervention (Week 4).

Change in performance on a virtual reality-based supermarket task assessing cognitive-motor integration, including divided attention and sustained attention during simulated everyday activities.

Baseline (Week 0) and post-intervention (Week 4).
Change in Dual-Task Performance (Box and Block Test)
Lasso di tempo: Baseline (Week 0) and post-intervention (Week 4).

Change in dual-task performance assessed using the Dual-Task Box and Block Test (BBT-DT), in which participants transfer blocks while simultaneously performing mental arithmetic.

Baseline (Week 0) and post-intervention (Week 4).
Feasibility of VR-CTT Training
Lasso di tempo: During the one-week pilot intervention (Stage 1).

Feasibility assessed by adherence to the planned VR-CTT training protocol, including the proportion of scheduled training sessions completed by participants.

During the one-week pilot intervention (Stage 1).
Simulator Sickness Symptoms
Lasso di tempo: After each VR training session during the one-week pilot (Stage 1).

Simulator sickness symptoms, including nausea, dizziness, headache, and eyestrain, assessed after VR training sessions using the Simulator Sickness Questionnaire (SSQ).

After each VR training session during the one-week pilot (Stage 1).
VR-CTT Usability and Participant Satisfaction
Lasso di tempo: At completion of the one-week pilot intervention (Stage 1).

Usability and participant satisfaction with the VR-CTT system assessed using post-training feedback questionnaires addressing comfort, ease of use, and overall experience.

At completion of the one-week pilot intervention (Stage 1).

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 dicembre 2026

Completamento primario (Stimato)

1 dicembre 2029

Completamento dello studio (Stimato)

1 dicembre 2029

Date di iscrizione allo studio

Primo inviato

10 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

10 novembre 2026

Primo Inserito (Effettivo)

17 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi